Keywords

herpes zoster, recombinant zoster vaccine, shingles, Shingrix, vaccination, zoster vaccine live, Zostavax

Authors

1. Brogie, Jackie D.
2. Rumph, Joshua H.
3. Chaplin, Michelle D. PharmD, BCACP, CDE
4. Drake, Nicole MSM, PA-C
5. Hodge, Bryan K. DO
6. Owens, Ryan E. PharmD, BCPS

Abstract

Abstract: The recombinant zoster vaccine (Shingrix) was approved to help combat the incidence of shingles in patients age 50 years and older and the CDC now recommends it over the zoster vaccine live (Zostavax). This article highlights practical considerations to help clinicians appropriately apply the most recent vaccine recommendations to their patients.